Boston Scientific (BSX) Upgraded at TheStreet

TheStreet upgraded shares of Boston Scientific (NYSE:BSX) from a c+ rating to a b rating in a research report sent to investors on Thursday.

A number of other brokerages have also commented on BSX. Canaccord Genuity lowered their price objective on Boston Scientific from $36.00 to $35.00 and set a buy rating for the company in a research report on Wednesday, November 29th. Zacks Investment Research lowered Boston Scientific from a hold rating to a sell rating in a research report on Tuesday, January 9th. BMO Capital Markets reiterated a buy rating and issued a $30.00 price objective on shares of Boston Scientific in a research report on Friday, October 13th. JPMorgan Chase & Co. reiterated a buy rating on shares of Boston Scientific in a research report on Wednesday, November 29th. Finally, Royal Bank of Canada upgraded Boston Scientific from an outperform rating to a top pick rating in a research report on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $31.00.

Shares of Boston Scientific (NYSE BSX) traded up $0.08 during trading hours on Thursday, hitting $27.73. The stock had a trading volume of 6,902,910 shares, compared to its average volume of 10,862,131. Boston Scientific has a 52 week low of $23.29 and a 52 week high of $29.93. The firm has a market capitalization of $38,050.00, a price-to-earnings ratio of 45.46, a PEG ratio of 1.98 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.31. The firm had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The company’s revenue was up 5.6% on a year-over-year basis. During the same period last year, the company earned $0.27 earnings per share. analysts predict that Boston Scientific will post 1.25 EPS for the current fiscal year.

In other Boston Scientific news, insider Valley Gold Master Fund L. Sun acquired 408,006 shares of the business’s stock in a transaction dated Tuesday, November 28th. The shares were acquired at an average price of $0.45 per share, for a total transaction of $183,602.70. Also, EVP Michael P. Phalen sold 15,835 shares of Boston Scientific stock in a transaction dated Saturday, December 29th. The shares were sold at an average price of $25.25, for a total value of $399,833.75. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 96,585 shares of company stock worth $2,578,197. Company insiders own 0.74% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Sit Investment Associates Inc. lifted its holdings in shares of Boston Scientific by 37.8% during the 3rd quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock valued at $4,134,000 after purchasing an additional 38,855 shares in the last quarter. Greenwood Capital Associates LLC lifted its holdings in shares of Boston Scientific by 71.7% during the 3rd quarter. Greenwood Capital Associates LLC now owns 91,579 shares of the medical equipment provider’s stock valued at $2,671,000 after purchasing an additional 38,249 shares in the last quarter. Knights of Columbus Asset Advisors LLC lifted its holdings in shares of Boston Scientific by 94.9% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 38,600 shares of the medical equipment provider’s stock valued at $1,126,000 after purchasing an additional 18,800 shares in the last quarter. LS Investment Advisors LLC lifted its holdings in shares of Boston Scientific by 5.8% during the 3rd quarter. LS Investment Advisors LLC now owns 40,621 shares of the medical equipment provider’s stock valued at $1,185,000 after purchasing an additional 2,209 shares in the last quarter. Finally, Chevy Chase Trust Holdings Inc. lifted its holdings in shares of Boston Scientific by 1.4% during the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 1,197,587 shares of the medical equipment provider’s stock valued at $34,934,000 after purchasing an additional 16,992 shares in the last quarter. Institutional investors and hedge funds own 90.42% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://stocknewstimes.com/2018/01/22/boston-scientific-bsx-upgraded-at-thestreet.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply